LearnGlossaryMarketStocksSuperinvestorsSign in

INSM

Insmed Incorporated

Healthcare · $27.9B market cap

Verdict

We can't put a fair value on INSM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-5.8% a year✗
Sales growth22.9% a year✓
Free cash flow growth—?
Return on invested capital-59.6%✗

Follow INSM

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds INSM. In Q2 2026, 1 opened a position. Who we track

Lee Ainslie

Maverick Capital · as of Q2 2026

$229.3M

2,150,762 shares

Moves in Q2 2026

New position: Lee Ainslie

Insider activity

Since Sep 9, 2026: no open-market purchases and 1 sale worth $3.1M. Why purchases matter

Sales

Brennan David R

director · 2026-09-09

Sold

$3.1M

About Insmed Incorporated

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works